ZHEJIANG YONGTAI
GenericsZHEJIANG YONGTAI is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.
ZHEJIANG YONGTAI's Key Drugs
ZHEJIANG YONGTAI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZHEJIANG YONGTAI's Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG YONGTAI over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG YONGTAI's Therapeutic Areas
ZHEJIANG YONGTAI's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG YONGTAI's Top Competitors
ZHEJIANG YONGTAI's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, WAYLIS THERAP, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZHEJIANG YONGTAI Pipeline Snapshot
Active clinical trials for ZHEJIANG YONGTAI across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2019-11-04
- Latest
- 2026-05-01
- Applications
- 4